Last10K.com

Sonoma Pharmaceuticals, Inc. (SNOA) SEC Filing 10-K Annual report for the fiscal year ending Sunday, March 31, 2019

Sonoma Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1317410 Ticker: SNOA
Document and Entity Information - USD ($)
12 Months Ended
Mar. 31, 2019
Jun. 28, 2019
Sep. 28, 2018
Document And Entity Information   
Entity Registrant NameSonoma Pharmaceuticals, Inc.  
Entity Central Index Key0001367083  
Document Type10-K  
Document Period End DateMar. 31, 2019  
Amendment Flagfalse  
Current Fiscal Year End Date--03-31  
Is Entity a Well-known Seasoned Issuer?No  
Is Entity a Voluntary Filer?No  
Is Entity's Reporting Status Current?Yes  
Entity Filer CategoryNon-accelerated Filer  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2019  
Entity public float  $ 9,056,417
Entity Common Stock, Shares Outstanding 1,328,891 
Entity Emerging Growth Companyfalse  
Entity Small Businesstrue  
Entity Shell Companyfalse  
Interactive Data CurrentYes  
Incorporation StateDE  
Entity File Number001-33216  

View differences made from one year to another to evaluate Sonoma Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Sonoma Pharmaceuticals, Inc..

Continue

Assess how Sonoma Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Sonoma Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity
Consolidated Statements Of Comprehensive (Loss) Income
1. Organization And Recent Developments
1. Organization And Recent Developments (Details Narrative)
10. Long-Term Debt
10. Long-Term Debt (Details - Minimum Note Payments)
10. Long-Term Debt (Details Narrative)
10. Long-Term Debt (Tables)
11. Capital Leases
11. Capital Leases (Details Narrative)
11. Capital Leases (Details)
11. Capital Leases (Tables)
12. Commitments And Contingencies
12. Commitments And Contingencies (Details)
12. Commitments And Contingencies (Tables)
12. Commitments And Contingenices (Details Narrative)
13. Stockholders' Equity
13. Stockholders' Equity (Details Narrative)
14. Stock-Based Compensation
14. Stock-Based Compensation (Details Narrative)
14. Stock-Based Compensation (Details-Assumptions)
14. Stock-Based Compensation (Details-Option Activity)
14. Stock-Based Compensation (Details-Plans)
14. Stock-Based Compensation (Details-Restricted Stock Activity)
14. Stock-Based Compensation (Details-Stock-Based Compensation)
14. Stock-Based Compensation (Tables)
15. Income Taxes
15. Income Taxes (Details Narrative)
15. Income Taxes (Details-Deferred Taxes)
15. Income Taxes (Details-Income Source)
15. Income Taxes (Details-Income Tax Expense)
15. Income Taxes (Details-Reconciliation Of Tax Rate)
15. Income Taxes (Tables)
16. Employee Benefit Plan
16. Employee Benefit Plan (Details Narrative)
17. Geographic Information
17. Geographic Information (Details - Geographic Regions)
17. Geographic Information (Details Narrative)
17. Geographic Information (Tables)
18. Subsequent Events
18. Subsequent Events (Details Narrative)
2. Liquidity And Financial Condition
2. Liquidity And Financial Condition (Details Narrative)
3. Summary Of Significant Accounting Policies
3. Summary Of Significant Accounting Policies (Details - Antidilutive Shares)
3. Summary Of Significant Accounting Policies (Details - Disaggregation Of Revenue)
3. Summary Of Significant Accounting Policies (Details Narrative)
3. Summary Of Significant Accounting Policies (Details-Useful Lives)
3. Summary Of Significant Accounting Policies (Policies)
3. Summary Of Significant Accounting Policies (Tables)
4. Accounts Receivable
4. Accounts Receivable (Details)
4. Accounts Receivable (Tables)
5. Inventories
5. Inventories (Details)
5. Inventories (Tables)
6. Prepaid Expenses And Other Current Assets
6. Prepaid Expenses And Other Current Assets (Details Narrative)
6. Prepaid Expenses And Other Current Assets (Details)
6. Prepaid Expenses And Other Current Assets (Tables)
7. Property And Equipment
7. Property And Equipment (Details Narrative)
7. Property And Equipment (Details)
7. Property And Equipment (Tables)
8. Accrued Expenses And Other Current Liabilities
8. Accrued Expenses And Other Current Liabilities (Details)
8. Accrued Expenses And Other Current Liabilities (Tables)
9. Common Stock Liability
9. Common Stock Liability (Details Narrative)

Material Contracts, Statements, Certifications & more

Sonoma Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consent
Exhibit 31.1: Certification Of Chief Executive Officer
Exhibit 31.2: Certification Of Chief Financial Officer
Exhibit 32.1: Certification
Ticker: SNOA
CIK: 1367083
Form Type: 10-K Annual Report
Accession Number: 0001683168-19-002069
Submitted to the SEC: Mon Jul 01 2019 4:54:38 PM EST
Accepted by the SEC: Mon Jul 01 2019
Period: Sunday, March 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/snoa/0001683168-19-002069.htm